Yuki Katayama Selected Research

Mycoplasmal Pneumonia of Swine (Swine Mycoplasmal Pneumonia)

4/2014	Genetic selection for resistance to mycoplasmal pneumonia of swine (MPS) in the Landrace line influences the expression of soluble factors in blood after MPS vaccine sensitization.
10/2013	Immunological characterization of peripheral blood leukocytes using vaccine for mycoplasmal pneumonia of swine (MPS) in swine line selected for resistance to MPS.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yuki Katayama Research Topics

Disease

13	Neoplasms (Cancer) 01/2022 - 10/2012
11	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2022 - 01/2019
3	Lung Neoplasms (Lung Cancer) 01/2022 - 01/2020
3	Infections 01/2022 - 10/2012
2	Inflammation (Inflammations) 01/2022 - 11/2017
2	Adenocarcinoma of Lung 08/2019 - 01/2018
2	Atherosclerosis 04/2016 - 01/2013
2	Mycoplasmal Pneumonia of Swine (Swine Mycoplasmal Pneumonia) 04/2014 - 10/2013
1	Candidiasis (Moniliasis) 01/2022
1	Genomic Instability 01/2022
1	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 07/2021
1	Disease Progression 12/2019
1	Sarcopenia 04/2019
1	Acidosis 03/2019
1	Hypoxia (Hypoxemia) 03/2019
1	Starvation 03/2019
1	Neoplasm Metastasis (Metastasis) 03/2019
1	Pericardial Effusion 01/2019
1	Cardiac Arrhythmias (Arrythmia) 01/2019
1	Exanthema (Rash) 01/2019
1	Hypotension (Low Blood Pressure) 01/2019
1	Muscle Weakness 01/2019
1	Necrosis 01/2019
1	Pericarditis 01/2019
1	Constipation 01/2019
1	Small Cell Carcinoma 01/2018
1	Autolysis 10/2013
1	Body Weight (Weight, Body) 01/2013
1	Virus Diseases (Viral Diseases) 10/2012
1	Liver Diseases (Liver Disease) 10/2012
1	Hepatocellular Carcinoma (Hepatoma) 10/2012
1	Liver Neoplasms (Liver Cancer) 10/2012

Drug/Important Bio-Agent (IBA)

6	Immune Checkpoint InhibitorsIBA 02/2022 - 01/2019
4	Tyrosine Kinase InhibitorsIBA 01/2022 - 01/2019
3	Pharmaceutical PreparationsIBA 01/2022 - 07/2021
3	ErbB Receptors (EGF Receptor)IBA 08/2019 - 01/2018
2	Anaplastic Lymphoma KinaseIBA 01/2022 - 12/2021
2	Interleukin-17 (Interleukin 17)IBA 01/2022 - 11/2017
2	osimertinibIBA 01/2022 - 01/2020
2	Indicators and Reagents (Reagents)IBA 04/2019 - 05/2017
2	CathepsinsIBA 05/2017 - 01/2015
2	VaccinesIBA 04/2014 - 10/2013
1	AfatinibIBA 01/2022
1	VimentinIBA 01/2022
1	Biological ProductsIBA 01/2022
1	dacomitinibIBA 01/2022
1	Gefitinib (Iressa)FDA Link 01/2022
1	JNK Mitogen-Activated Protein KinasesIBA 12/2021
1	Probucol (Lorelco)FDA Link 07/2021
1	Antinuclear AntibodiesIBA 11/2020
1	atezolizumabIBA 10/2020
1	Glucose (Dextrose)FDA LinkGeneric 03/2019
1	Angiogenesis InhibitorsIBA 03/2019
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2019
1	Alkaline PhosphataseIBA 01/2019
1	Creatine Kinase (Creatine Phosphokinase)IBA 01/2019
1	LaxativesIBA 01/2019
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018
1	Peptides (Polypeptides)IBA 11/2017
1	staphylococcal delta toxinIBA 11/2017
1	AlarminsIBA 11/2017
1	Antineoplastic Agents (Antineoplastics)IBA 05/2017
1	Liposomes (Liposome)IBA 05/2017
1	SphingomyelinsIBA 04/2016
1	Interferon Type IIBA 01/2015
1	InterferonsIBA 01/2015
1	Capsid Proteins (Capsid Protein)IBA 01/2015
1	AntigensIBA 10/2013
1	Methicillin (Metin)FDA Link 10/2013
1	LipidsIBA 01/2013
1	oxidized low density lipoproteinIBA 01/2013
1	Apolipoproteins E (ApoE)IBA 01/2013
1	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2013
1	ApolipoproteinsIBA 01/2013
1	IncretinsIBA 01/2013
1	VildagliptinIBA 01/2013
1	Pro(3)- glucose-dependent insulinotropic polypeptideIBA 01/2013
1	Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA 01/2013
1	Biomarkers (Surrogate Marker)IBA 10/2012
1	MicroRNAs (MicroRNA)IBA 10/2012

Therapy/Procedure

5	Therapeutics 02/2022 - 01/2019
5	Immunotherapy 11/2020 - 01/2019
3	Drug Therapy (Chemotherapy) 02/2022 - 01/2018